Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

With its decentralised, transparent, controlled ... trust” through blockchain for the global pharma supply chain. Boehringer Ingelheim and IBM have partnered, enabling Boehringer to use IBM ...

We got onto the buzz about “transparent aluminum” as a result of a Tweet from whence the image above came. This Tweet was posted by [Jo Pitesky], a Science Systems Engineer at the Jet ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

New research by The Worldcom Public Relations Group has ranked pharmaceutical companies according to their usage of digital channels – with Bayer, Pfizer and Boehringer Ingelheim coming out on top.

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...